Steatosis of LiverNCT06373536
Comparison of MRI-PDFF to TAEUS FLIP Device to Estimate Liver Fat Fraction in Adults
An observational study of Steatosis of Liver, run by Endra Lifesciences at 1 site in Germany.
Trial summary
Primary nonalcoholic fatty Liver disease (NAFLD) is an excess of fat in the liver (steatosis) that is not a result of excessive alcohol consumption or other secondary causes11. NAFLD is defined by the presence of hepatic fat content (steatosis) in ≥ 5% of hepatocytes and is currently the most common liver disease… Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Steatosis of Liver
- What is being tested?
- Thermoacoustic imaging, MRI and Ultrasound imaging
- How many people
- 80 participants
- Where
- 1 siteGermany
- Study dates
- 21 Jun 2024to 1 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients referred to radiology for abdominal imaging and suspected of having steatotic liver disease.
Who may be able to join
- Study participants are 18-70 years of age
- Existing MRI-PDFF not older than 6 weeks or routine MRI-PDFF in the following 6 weeks
- Be able to understand, read, and provide written informed consent in German
- Tolerant to ultrasound and MRI examinations
- Able to lay flat for 20 minutes
Who cannot join
- Metal or electronic implants, including, but not limited to: pacemakers, metal clips, drug delivery pumps, hip implants, and neural stimulation devices.
- Known pregnancy the day of consent, or becoming pregnant during study participation
- Liver disease other than NAFLD/NASH including, but not limited to, hepatitis, cirrhosis, hepatocellular carcinoma.
- Patients with broken, or injured skin, in the right upper abdominal quadrant.
- BMI over 43 kg/m2
Trial locations and contacts
1 site in 1 country.
Germany1 site
Klinikum der Universität München Großhadern Klinik und Poliklink für Radiologie
München, 81377
Monika Dienst, M.Sc., +49 89 4400 76642, monika.dienst@med.uni-muenchen.de
Dirk-Andre Clevert, Prof. Dr. med.
About this study
Official title: Comparison of Thermoacoustic Enhanced Ultrasound for Estimating Liver Fat Fraction to MRI-PDFF
Primary nonalcoholic fatty Liver disease (NAFLD) is an excess of fat in the liver (steatosis) that is not a result of excessive alcohol consumption or other secondary causes11. NAFLD is defined by the presence of hepatic fat content (steatosis) in ≥ 5% of hepatocytes and is currently the most common liver disease worldwide14 . Non-Alcoholic Fatty Liver Disease (NAFLD) is the world\'s most common liver disease and affects around 33% of the adult population.
Nonalcoholic steatohepatitis (NASH), a progressive form of nonalcoholic fatty liver disease (NAFLD), is a growing clinical concern associated with the increasing prevalence of obesity, type 2 diabetes, and metabolic syndrome. NASH is characterized by the presence of hepatic steatosis, inflammation, and hepatocellular injury and is predicted to be the leading indication for liver transplantation by 20201. Patients with NASH have an increased risk of developing cirrhosis and its complications, such as ascites, variceal hemorrhage, hepatic encephalopathy, hepatocellular carcinoma, and liver failure. The prevalence worldwide of NAFLD in the general population is estimated at 20-35%2 . Around 2-3% of the population have NASH.
In patients with type 2 diabetes, the prevalence is even over 50% (55.5% globally, 68% in Europe). In Germany, the NAFLD prevalence was 23% in 2016 and will be around 26% in 2030. The prevalence of non-alcoholic alcoholic steatohepatitis (NASH), i.e. the progressive form of NAFLD, is estimated at 4% of the adult population in Germany and will increase to 6% by 2030. This means that NAFLD is already the most common chronic liver disease worldwide and one of the leading causes of liver-related complications (cirrhosis, decompensation, hepatocellular carcinoma, liver transplantation) and deaths. NAFLD and NASH are largely underdiagnosed worldwide.
Read the detailed description
Early detection and surveillance of steatosis hepatis improves the chances of management or even improvement of the disease before irreversible damage occurs12. Liver tissue biopsy is the current reference standard for the diagnosis and severity of steatosis hepatis. However, due to its invasiveness, biopsy collection is not suitable for screening or regular follow-up. The diagnostic techniques of magnetic resonance spectroscopy (MRS) and MRI-PDFF (proton density fat fraction) for the assessment of liver fat content have been shown to correlate well with the results of liver biopsy, but are particularly associated with high costs, low availability, long examination times and exclusion of patients with metal implants. Conventional B-scan ultrasonography is the most commonly used imaging modality for assessing steatosis hepatis based on qualitative image features of the liver. These include an echo-enhanced internal reflex pattern of the liver parenchyma, loss of signal in depth, blurred demarcation of the blood vessels and diaphragm, or areas of focal obesity. The sensitivity and specificity of conventional sonography is high in severe steatosis hepatis. On the other hand, the sensitivity is significantly worse in mild cases. In addition, intra- and interobserver reliability are poor in the assessment of steatosis hepatis of the conventional B-scan.
Quantitative ultrasound-based methods are the current standard of practice for point-of-care, noninvasive liver fat assessment. However, due to low penetration depth and confounding factors, invalid or poor-quality measurements are often encountered in large patients, or patients with liver fibrosis. In contrast to purely ultrasound-based approaches, thermoacoustic (TA) approaches are sensitive to tissue composition chemistry rather than acoustic scattering and/or attenuation, making TA measurements of liver fat content relatively insensitive to liver fibrosis or patient size.
Thermoacoustic (imaging) technology is non-invasive and combines short pulses of radio-frequency energy to create ultrasound signals (acoustic waves) in tissue to create images, or measurements, of fat in body tissues. The radio-frequency energy that is used to create thermoacoustic ultrasound signals is very similar to that used by cell phones and MRI scanners. Thermoacoustic signals are created in proportion to how well tissue is able to conduct electricity. Lean tissues are highly conductive while fatty tissues are not, and thus, thermoacoustics is able to differentiate lean and fatty tissues. A primary interest in detecting, and monitoring metabolic health, is measuring liver fat content. Thermoacoustic approaches to fat measurement in the liver have several unique advantages compared to other currently used technologies, including ultrasound and MRI. Medical ultrasound scanners are widely available but often have difficulty making high-quality images, and reliable measurements, in larger patients or deeper tissues. Thermoacoustic ultrasound signals are formed in the tissue allowing measurements of fat to be made at depths that may not be possible with conventional ultrasound systems. While MRI is the most accurate noninvasive method to estimate fat in tissue, it has limited availability and is very expensive compared to thermoacoustics, and thus impractical for widespread use that is needed to address the growing problem of fatty liver disease and metabolic syndrome.
Thermoacoustic approaches to fat measurement in tissue are exceptionally safe using radio frequency energy levels similar to MRI, with tissue heating that is less than a 0.001 degrees Celsius per pulse in temperature. ENDRA has developed a noninvasive bedside device called the TAEUS®-FLIP system for measuring fat in liver tissue. The TAEUS®-FLIP exam is performed during a routine exam and takes between 5-10 minutes to perform. The TAEUS®-FLIP system has the potential to bring wide access to accurate liver fat measurements to a wide range of patient populations and to address the unmet need for detecting and monitoring patients with fatty liver disease and metabolic syndrome.
In this study, the investigators want to compare TAEUS® FLIP with MRI-PDFF to gain insight into the potential of thermoacoustic methods to assess liver fat content, similar to MRI-PDFF. Unlike conventional quantitative ultrasound methods, the thermoacoustic approach has demonstrated the potential to obtain estimates of liver fat fraction in individuals with high BMI (45), and those with confirmed liver fibrosis.
- Conditions
- Steatosis of Liver
- Being tested
- Thermoacoustic imaging, MRI and Ultrasound imaging
- Keywords
- MRI-PDFF, Thermoacoustics
- Medical subject headings
- Fatty Liver
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Thermoacoustic imaging, MRI and Ultrasound imagingDiagnostic test
This is a Thermoacoustic imaging exam that will last 10-15 minutes. Distinguishing; assessment of steatosis liver disease in obese and morbidly obese patients.
What is being measured
The primary outcome is the main question the study is designed to answer.
Thermoacoustic Fat Measurements
Perform thermoacoustic fat measurements for 80 participants, by one or more qualified operators, over the span of the study in order to determine the correlation of thermoacoustic derived fat fraction measures of steatotic liver disease to measurements obtained by MRI-PDFF.
Measured: May 2024 to September 2025
Estimate Accuracy of Thermoacoustic Fat Fraction
Estimate the accuracy of thermoacoustic derived fat fraction measurements of steatotic liver disease by comparing to the established standard of MRI-PDFF measurements of liver fat fraction
Measured: May 2024 to September 2025
Secondary outcomes (2)
Usability Metric
To derive usability in terms of exam failure rate, where a single exam failure is defined as a failure to produce a fat fraction value for the subject. Multiple qualified users will be trained to operate, and evaluate, the TAEUS® FLIP system usability.
Measured: May 2024 to January 2025
Estimate Operator Variability
Estimate the intra- and inter- operator variability of thermoacoustic derived liver fat fraction in 10 participants, by acquiring fat fraction measurements in replicate, by multiple operators.
Measured: May 2024 to January 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Apr 2024
- Study start21 Jun 2024 (estimated)
- Primary completion21 Jun 2025 (estimated)
- Study completion1 Sep 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Steatosis of LiverStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Endra Lifesciences
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06373536
- Sponsor's protocol ID
- LMU-RAD-01167
- Status last verified
- Apr 2024
- First submitted
- 5 Apr 2024
- Last updated
- 7 Jun 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Data sharing is contingent on the data sharing policy of principal investigator and the study site.
Study at a glance
From the registry record, last updated by the sponsor on 7 Jun 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Thermoacoustic Enhanced Ultrasound for Estimating Liver Fat Fraction to MRI-PDFF
- ClinicalTrials.gov ID
- NCT06373536
- Acronym / sponsor ID
- LMU-RAD-01167
- Conditions
- Steatosis of Liver
- Keywords
- MRI-PDFF, Thermoacoustics
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Endra LifesciencesIndustry (pharma, biotech, devices)
- Study start
- 21 Jun 2024 (estimated)
- Primary completion
- 21 Jun 2025 (estimated)
- Study completion
- 1 Sep 2025 (estimated)
- First posted
- 18 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Primary nonalcoholic fatty Liver disease (NAFLD) is an excess of fat in the liver (steatosis) that is not a result of excessive alcohol consumption or other secondary causes11. NAFLD is defined by the presence of hepatic fat content (steatosis) in ≥ 5% of hepatocytes and is currently the most common liver disease worldwide14 . Non-Alcoholic Fatty Liver Disease (NAFLD) is the world\'s most common liver disease and affects around 33% of the adult population.
Nonalcoholic steatohepatitis (NASH), a progressive form of nonalcoholic fatty liver disease (NAFLD), is a growing clinical concern associated with the increasing prevalence of obesity, type 2 diabetes, and metabolic syndrome. NASH is characterized by the presence of hepatic steatosis, inflammation, and hepatocellular injury and is predicted to be the leading indication for liver transplantation by 20201. Patients with NASH have an increased risk of developing cirrhosis and its complications, such as ascites, variceal hemorrhage, hepatic encephalopathy, hepatocellular carcinoma, and liver failure. The prevalence worldwide of NAFLD in the general population is estimated at 20-35%2 . Around 2-3% of the population have NASH.
In patients with type 2 diabetes, the prevalence is even over 50% (55.5% globally, 68% in Europe). In Germany, the NAFLD prevalence was 23% in 2016 and will be around 26% in 2030. The prevalence of non-alcoholic alcoholic steatohepatitis (NASH), i.e. the progressive form of NAFLD, is estimated at 4% of the adult population in Germany and will increase to 6% by 2030. This means that NAFLD is already the most common chronic liver disease worldwide and one of the leading causes of liver-related complications (cirrhosis, decompensation, hepatocellular carcinoma, liver transplantation) and deaths. NAFLD and NASH are largely underdiagnosed worldwide.
Detailed description
Early detection and surveillance of steatosis hepatis improves the chances of management or even improvement of the disease before irreversible damage occurs12. Liver tissue biopsy is the current reference standard for the diagnosis and severity of steatosis hepatis. However, due to its invasiveness, biopsy collection is not suitable for screening or regular follow-up. The diagnostic techniques of magnetic resonance spectroscopy (MRS) and MRI-PDFF (proton density fat fraction) for the assessment of liver fat content have been shown to correlate well with the results of liver biopsy, but are particularly associated with high costs, low availability, long examination times and exclusion of patients with metal implants. Conventional B-scan ultrasonography is the most commonly used imaging modality for assessing steatosis hepatis based on qualitative image features of the liver. These include an echo-enhanced internal reflex pattern of the liver parenchyma, loss of signal in depth, blurred demarcation of the blood vessels and diaphragm, or areas of focal obesity. The sensitivity and specificity of conventional sonography is high in severe steatosis hepatis. On the other hand, the sensitivity is significantly worse in mild cases. In addition, intra- and interobserver reliability are poor in the assessment of steatosis hepatis of the conventional B-scan.
Quantitative ultrasound-based methods are the current standard of practice for point-of-care, noninvasive liver fat assessment. However, due to low penetration depth and confounding factors, invalid or poor-quality measurements are often encountered in large patients, or patients with liver fibrosis. In contrast to purely ultrasound-based approaches, thermoacoustic (TA) approaches are sensitive to tissue composition chemistry rather than acoustic scattering and/or attenuation, making TA measurements of liver fat content relatively insensitive to liver fibrosis or patient size.
Thermoacoustic (imaging) technology is non-invasive and combines short pulses of radio-frequency energy to create ultrasound signals (acoustic waves) in tissue to create images, or measurements, of fat in body tissues. The radio-frequency energy that is used to create thermoacoustic ultrasound signals is very similar to that used by cell phones and MRI scanners. Thermoacoustic signals are created in proportion to how well tissue is able to conduct electricity. Lean tissues are highly conductive while fatty tissues are not, and thus, thermoacoustics is able to differentiate lean and fatty tissues. A primary interest in detecting, and monitoring metabolic health, is measuring liver fat content. Thermoacoustic approaches to fat measurement in the liver have several unique advantages compared to other currently used technologies, including ultrasound and MRI. Medical ultrasound scanners are widely available but often have difficulty making high-quality images, and reliable measurements, in larger patients or deeper tissues. Thermoacoustic ultrasound signals are formed in the tissue allowing measurements of fat to be made at depths that may not be possible with conventional ultrasound systems. While MRI is the most accurate noninvasive method to estimate fat in tissue, it has limited availability and is very expensive compared to thermoacoustics, and thus impractical for widespread use that is needed to address the growing problem of fatty liver disease and metabolic syndrome.
Thermoacoustic approaches to fat measurement in tissue are exceptionally safe using radio frequency energy levels similar to MRI, with tissue heating that is less than a 0.001 degrees Celsius per pulse in temperature. ENDRA has developed a noninvasive bedside device called the TAEUS®-FLIP system for measuring fat in liver tissue. The TAEUS®-FLIP exam is performed during a routine exam and takes between 5-10 minutes to perform. The TAEUS®-FLIP system has the potential to bring wide access to accurate liver fat measurements to a wide range of patient populations and to address the unmet need for detecting and monitoring patients with fatty liver disease and metabolic syndrome.
In this study, the investigators want to compare TAEUS® FLIP with MRI-PDFF to gain insight into the potential of thermoacoustic methods to assess liver fat content, similar to MRI-PDFF. Unlike conventional quantitative ultrasound methods, the thermoacoustic approach has demonstrated the potential to obtain estimates of liver fat fraction in individuals with high BMI (45), and those with confirmed liver fibrosis.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients referred to radiology for abdominal imaging and suspected of having steatotic liver disease.
Key inclusion criteria (5 listed)
- Study participants are 18-70 years of age
- Existing MRI-PDFF not older than 6 weeks or routine MRI-PDFF in the following 6 weeks
- Be able to understand, read, and provide written informed consent in German
- Tolerant to ultrasound and MRI examinations
- Able to lay flat for 20 minutes
Key exclusion criteria (5 listed)
- Metal or electronic implants, including, but not limited to: pacemakers, metal clips, drug delivery pumps, hip implants, and neural stimulation devices.
- Known pregnancy the day of consent, or becoming pregnant during study participation
- Liver disease other than NAFLD/NASH including, but not limited to, hepatitis, cirrhosis, hepatocellular carcinoma.
- Patients with broken, or injured skin, in the right upper abdominal quadrant.
- BMI over 43 kg/m2
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Thermoacoustic imaging, MRI and Ultrasound imagingThis is a Thermoacoustic imaging exam that will last 10-15 minutes. Distinguishing; assessment of steatosis liver disease in obese and morbidly obese patients. | Diagnostic test | – |
Primary outcome
Thermoacoustic Fat Measurements
Time frame: May 2024 to September 2025
Perform thermoacoustic fat measurements for 80 participants, by one or more qualified operators, over the span of the study in order to determine the correlation of thermoacoustic derived fat fraction measures of steatotic liver disease to measurements obtained by MRI-PDFF.
Estimate Accuracy of Thermoacoustic Fat Fraction
Time frame: May 2024 to September 2025
Estimate the accuracy of thermoacoustic derived fat fraction measurements of steatotic liver disease by comparing to the established standard of MRI-PDFF measurements of liver fat fraction
2 secondary outcomes
Usability Metric
Time frame: May 2024 to January 2025
Estimate Operator Variability
Time frame: May 2024 to January 2025
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jun 2024.
- Individual participant dataSharing planned: Undecided. Data sharing is contingent on the data sharing policy of principal investigator and the study site.
Related trials for Steatosis of Liver
Not yet recruiting
Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors
Hepatic Steatosis, Fatty Liver
Recruiting
Dietary Intervention Study on Liver Health in Young Adults
Liver Health
Recruiting
NAFLD Clinical Care Pathway
NAFLD, MASLD
RecruitingPhase 3
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
RecruitingPhase 1
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
Non-alcoholic Fatty Liver Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Steatosis of Liver, run by Endra Lifesciences at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 7 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Dirk-Andre Clevert, Prof. Dr. (+49 89 44007 3635, Dirk.Clevert@med.uni-muenchen.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Thermoacoustic Fat Measurements (time frame: May 2024 to September 2025). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jun 2024.